Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation

  • Corcept Therapeutics (CORT) demonstrates exceptional price momentum with shares up more than 50% over the past year.
  • CORT’s fundamentals are robust with revenue and earnings both projected to grow this year.
  • Technical indicators remain bullish with a 100% “Buy” opinion from Barchart.
  • Analyst sentiment is mixed —ratings range from “Strong Buy” to “Strong Sell” — and valuation concerns persist.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.